Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 2/20 | 0.71 |
| ▸ | TSHR | P16473 | 4/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.42 |
| ▸ | KAT6A | Q92794 | 1/20 | 0.40 |
| ▸ | PSIP1 | O75475 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 2/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9229864 | 0.91 | ACHE (0.65) | ACHETSHRALDH1A1KAT6APSIP1 | |
| SCHEMBL29488781 | 0.84 | — | — | |
| SCHEMBL11837 | 0.84 | — | — | |
| SCHEMBL28557764 | 0.82 | ACHE (0.83) | ACHETSHRALDH1A1KAT6AKMT2A | |
| Formaldehyde SCHEMBL27341516 | 0.82 | ACHE (0.83) | ACHETSHRALDH1A1KAT6ALMNA | |
| SCHEMBL28019040 | 0.82 | ACHE (0.83) | ACHETSHRALDH1A1TDP1ALOX15 | |
| Hydrochloric Acid SCHEMBL29088489 | 0.82 | ACHE (0.94) | ACHETSHRALDH1A1TDP1SMN1; SMN2 | |
| SCHEMBL29176814 | 0.82 | — | — | |
| Fluoride SCHEMBL21816907 | 0.82 | ACHE (0.94) | ACHETSHRALDH1A1TDP1SMN1; SMN2 | |
| O-Xylene SCHEMBL994540 | 0.82 | TSHR (0.62) | ACHETSHRALDH1A1HSD17B10LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102531978-B | Preparation method of thiophenol | UNIV ZHEJIANG | 2013-12-18 | — | — | CN | claimed |
| CN-102531978-A | Preparation method of thiophenol | UNIV ZHEJIANG | 2012-07-04 | — | — | CN | claimed |
| CN-103958521-B | Pyrimidin-4-one derivatives and their use in the treatment, alleviation or prevention of viral diseases | 弗·哈夫曼-拉罗切有限公司 | 2016-10-19 | — | — | CN | disclosed |
| CN-103958475-B | Heteroaryl hydroxamic acid derivatives and their use in the treatment, alleviation or prevention of viral diseases | F. HOFFMANN-LA ROCHE AG (CH) | 2015-11-25 | — | — | CN | disclosed |
| EP-2456435-B1 | HETEROARYL BENZAMIDES, COMPOSITIONS AND METHODS OF USE | UNIV LELAND STANFORD JUNIOR (US) | 2015-06-24 | — | — | EP | disclosed |
| CN-103958475-A | Heteroaryl hydroxamic acid derivatives and their use in the treatment, alleviation or prevention of viral diseases | HOFFMANN LA ROCHE | 2014-07-30 | — | — | CN | disclosed |
| CN-102149717-B | Dioxa-bicyclo [3.2.1] octane-2, 3, 4-triol derivatives | PFIZER | 2014-05-14 | — | — | CN | disclosed |
| CN-102216265-B | Naphthylacetic acid | HOFFMANN LA ROCHE | 2014-04-30 | — | — | CN | disclosed |
| CN-103497199-A | Dioxa-bicyclo[3.2.1]octane-2, 3, 4-triol derivatives | PFIZER | 2014-01-08 | — | — | CN | disclosed |
| CN-102531978-B | Preparation method of thiophenol | UNIV ZHEJIANG | 2013-12-18 | — | — | CN | disclosed |
| CN-102099341-B | Aminotetrahydroindazoloacetic acids | HOFFMANN LA ROCHE | 2013-07-10 | — | — | CN | disclosed |
| CN-102875441-A | Plexxikon inc | PLEXXIKON INC | 2013-01-16 | — | — | CN | disclosed |
| US-20120225862-A1 | HETEROARYL BENZAMIDES, COMPOSITIONS AND METHODS OF USE | AUCKLAND UNIVSERVICES LIMITED (NZ) | 2012-09-06 | — | — | US | disclosed |
| CN-102531978-A | Preparation method of thiophenol | UNIV ZHEJIANG | 2012-07-04 | — | — | CN | disclosed |
| EP-2456435-A1 | HETEROARYL BENZAMIDES, COMPOSITIONS AND METHODS OF USE | The Board of Trustees of The Leland Stanford Junior University (US) | 2012-05-30 | — | — | EP | disclosed |
| CN-102216265-A | Naphthylacetic acid | HOFFMANN LA ROCHE | 2011-10-12 | — | — | CN | disclosed |
| CN-102099341-A | Aminotetrahydroindazoloacetic acids | HOFFMANN LA ROCHE | 2011-06-15 | — | — | CN | disclosed |
| WO-2011011514-A1 | HETEROARYL BENZAMIDES, COMPOSITIONS AND METHODS OF USE | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2011-01-27 | — | — | WO | disclosed |
| CN-101516837-A | Sulfonamide derivatives | HOFFMANN LA ROCHE (CH) | 2009-08-26 | — | — | CN | disclosed |
| CN-1845898-A | PPAR active compounds | PLEXXIKON INC (US) | 2006-10-11 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120225862-A1 | HETEROARYL BENZAMIDES, COMPOSITIONS AND METHODS OF USE | BRDT, NISCH, PAICS | ACHE 141/4885TSHR 3930/4885ALDH1A1 1336/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.